Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sandoz Neupogen Biosimilar Heads To ODAC; Cmte. May Be Students As Much As Advisors

Dec 08 2014

• By Derrick Gingery

Related Content

Sandoz’s Biosimilar Filing Is Culmination Of Paradigm Shift In FDA Drug Review

Jul 28 2014

Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway

Oct 15 2012

Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain

Sep 03 2012

Related Companies

Novartis AG

Amgen, Inc.

Teva Pharmaceutical Industries Ltd.

Celltrion, Inc.

Johnson & Johnson

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window